Carmine Therapeutics has entered a collaborative agreement with Takeda to develop gene therapies for rare diseases using Carmine's red blood cell extracellular vesicles platform. The deal, expected to be worth nearly $1 billion, includes an upfront payment and additional research funding, but an exact figure was not disclosed, and Takeda would gain the alternative for the programs' licensing once preclinical proof of concept studies have been completed.
Takeda, Carmine partner for nearly $1B gene therapies deal
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.